Picture of Physiomics logo

PYC Physiomics News Story

0.000.00%
gb flag iconLast trade - 00:00
IndustrialsHighly SpeculativeMicro CapSucker Stock

REG - Physiomics PLC - Contract Award

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221012:nRSL4870Ca&default-theme=true

RNS Number : 4870C  Physiomics PLC  12 October 2022

12 October 2022

 

Physiomics plc

("Physiomics") or ("the Company")

 

Contract award

 

Physiomics plc (AIM: PYC), the consultancy company offering expertise in
mathematical modelling and simulation to enable smarter decision making in
drug development for the biopharma industry, is pleased to announce that it
has signed an agreement to work with Cancer Research UK.

Physiomics will use its PKPD modelling capabilities to support the Cancer
Research UK sponsored early phase clinical development of ALETA-001, a CAR-T
cell engager candidate for the treatment of blood cancers developed by Aleta
Biotherapeutics. The PKPD modelling project is expected to be completed during
this calendar year.

Dr Jim Millen, CEO said: "We are delighted to be working with Cancer Research
UK, the world's leading cancer charity.  Although we have previously worked
with clients whose early clinical trials are sponsored by Cancer Research UK's
Centre for Drug Development, this project marks the first occasion on which
Physiomics has worked directly with Cancer Research UK."

 

Enquiries:

 

Physiomics
plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has
worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle
Therapeutics.

About Cancer Research UK's Centre for Drug Development  

Cancer Research UK has an impressive record of developing novel treatments for
cancer. The Cancer Research UK Centre for Drug Development has been pioneering
the development of new cancer treatments for 25 years, taking over 140
potential new anti-cancer agents into clinical trials in patients. It
currently has a portfolio of 21 new anti-cancer agents in preclinical
development, Phase I or early Phase II clinical trials. Six of these new
agents have made it to market including temozolomide for brain cancer,
abiraterone for prostate cancer and rucaparib for ovarian cancer. Two other
drugs are in late development Phase III trials.

About Aleta Biotherapeutics

Aleta's mission is to create cell therapeutics that provide robust and durable
clinical benefit for patients suffering from advanced hematologic cancers and
refractory solid tumors. Aleta's CAR-T Engager technology incorporates potent
multi-antigen targeting, optimal T cell fitness, and persistence to
aggressively attack cancers. We use this technology to build programs that
solve specific clinical issues, including cell therapy relapses due to antigen
loss and the challenge of overcoming solid tumor heterogeneity. Our lead
development program has won landmark clinical support from Cancer Research UK
and will enter Phase1/2 trials in 2023.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTGPGAUUUPPUBG

Recent news on Physiomics

See all news